The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
ATHENS, Ga.--(BUSINESS WIRE)--Dalan Animal Health, Inc. (“Dalan”), the biotech company pioneering insect health with the world’s first honey bee vaccine, is proud to announce its first product s...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corpor...
Heska (HSKA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.27 per share a year ago....
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corpor...
NEW YORK , April 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
Heska and privately-held Mars have agreed to a buyout offer of $120 per share. This deal underscores the high-growth potential of pet products companies....
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Heska Corporation (NASDAQ: HSKA) to Mars, Incorporated for $120.00 per share is fair to H...
Heska Corporation (NASDAQ:HSKA ) Q4 2022 Earnings Conference Call February 28, 2023 11:00 AM ET Company Participants Jon Aagaard - Investor Relations Kevin Wilson - Chief Executive Officer and Preside...
Heska (HSKA) delivered earnings and revenue surprises of 44.74% and 3.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...